Genomic characterization of highrecurrence risk papillary thyroid carcinoma in a southern Chinese population

Background: The objective of this study was to investigate genetic variations and the relationships between these
genetic variations and clinicopathological features of high-recurrence risk papillary thyroid carcinoma in a southern
Chinese population.
Methods: One hundred sixty-eight patients of high-recurrence risk papillary thyroid carcinoma were recruited for
this study from 2017 to 2018. Formalin-fixed paraffin-embedded tissue and the data of clinicopathological
characteristics were all collected and analyzed from these patients. We used next-generation sequencing
technology to investigate the targeted gene mutations and gene fusions of the pathology specimens.
Results: The frequency of candidate tumor driver gene mutation was 85.1% in 143 patients, including BRAF V600E
mutation in 119 patients(70.8%), RET fusion in 13 patients(7.7%), TERT promoter mutations in 11 patients(6.5%), RAS
(HRAS, NRAS, KRAS) gene mutations in 10 patients(6.0%), and other mutations involving TP53, PIK3CA, AKT1, PTEN and
NTRK1. Concomitant presence of more than two genetic aberrations was seen in 27 patients (16.1%). Our study
showed that BRAF V600E mutation is highly correlated with conventional PTC (p < 0.001), BRAF V600E and TERT
promoter mutation duet was associated with older patient age (> 45, p = 0.003) and higher disease stage of III or IV
(p = 0.002). RAS gene and BRAF V600E co-mutations were only seen in multifocal PTC (p = 0.015).
Conclusion: In our high-recurrence risk PTC cohort, most patients had more than one driver gene aberration.
Coexistence of BRAF V600E with TERT promoter mutations or with RAS mutations were significantly correlated with
worse clinicopathological characteristics.